The company launched ONAPGO™, a new treatment for Parkinson's disease, in April 2025 and saw significant growth in Qelbree prescriptions, which rose by 22%. Supernus reiterated its full year ...

Early in the second quarter, we launched ONAPGO, Supernus next growth product. It is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults ...

including the successful launch of ONAPGO and advancing its innovative R&D pipeline. With reiterated revenue guidance and strong cash reserves, Supernus is positioned for continued growth amid ...

ONAPGO™ (apomorphine hydrochloride) launched in the U.S. in April 2025. The Company reiterates full year 2025 financial guidance. ROCKVILLE, Md., May 06, 2025 (GLOBE NEWSWIRE) -- Supernus ...

President and CEO of Supernus. “In addition, we are pleased to be bringing ONAPGO to market, another growth driver for our business. ONAPGO represents a novel approach for adults with Parkinson ...

President and CEO of Supernus. "In addition, we are pleased to be bringing ONAPGO to market, another growth driver for our business. ONAPGO represents a novel approach for adults with Parkinson's ...

The launch of ONAPGO, a new growth product for Parkinson's disease, has shown encouraging initial responses from physicians. Supernus Pharmaceuticals Inc (NASDAQ:SUPN) has a strong balance sheet ...

ONAPGO™ (apomorphine hydrochloride) launched in the U.S. in April 2025. The Company reiterates full year 2025 financial guidance. ROCKVILLE, Md., May 06, 2025 (GLOBE NEWSWIRE) -- Supernus ...

ONAPGO (apomorphine hydrochloride) launched in the U.S. in April 2025. The Company reiterates full year 2025 financial guidance. ROCKVILLE, Md., May 06, 2025 (GLOBE NEWSWIRE) -- Supernus ...